scholarly journals Human Platelet Lysate Can Replace Fetal Calf Serum as a Protein Source to Promote Expansion and Osteogenic Differentiation of Human Bone-Marrow-Derived Mesenchymal Stromal Cells

Cells ◽  
2020 ◽  
Vol 9 (4) ◽  
pp. 918 ◽  
Author(s):  
Maria Karadjian ◽  
Anne-Sophie Senger ◽  
Christopher Essers ◽  
Sebastian Wilkesmann ◽  
Raban Heller ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Osteogenic Differentiation ◽  
Fetal Calf Serum ◽  
Culture Media ◽  
Human Platelet ◽  
Calf Serum ◽  
Calcium Content ◽  
Platelet Lysate ◽  
Protein Source ◽  
Human Platelet Lysate

Fetal calf serum (FCS) is frequently used as a growth factor and protein source in bone-marrow-derived mesenchymal stromal cell (BMSC) culture media, although it is a xenogenic product presenting multiple disadvantages including but not limited to ethical concerns. A promising alternative for FCS is human platelet lysate (hPL), which is produced out of human platelet concentrates and happens to be a stable and reliable protein source. In this study, we investigated the influence of hPL in an expansion medium (ESM) and an osteogenic differentiation medium (ODM) on the proliferation and osteogenic differentiation capacity of human BMSC. Therefore, we assessed population doublings during cell expansion, performed alizarin red staining to evaluate the calcium content in the extracellular matrix and determined the activity of alkaline phosphatase (ALP) as osteogenic differentiation correlates. The proliferation rate of BMSC cultured in ESM supplemented with hPL exceeded the proliferation rate of BMSC cultured in the presence of FCS. Furthermore, the calcium content and ALP activity was significantly higher in samples incubated in hPL-supplemented ODM, especially in the early phases of differentiation. Our results show that hPL can replace FCS as a protein supplier in cell culture media and does not negatively affect the osteogenic differentiation capacity of BMSC.

scholarly journals 3D gelatin-chitosan hybrid hydrogels combined with human platelet lysate highly support human mesenchymal stem cell proliferation and osteogenic differentiation

2019 ◽  
Vol 10 ◽  
pp. 204173141984585 ◽  
Author(s):  
Federica Re ◽  
Luciana Sartore ◽  
Vladimira Moulisova ◽  
Marco Cantini ◽  
Camillo Almici ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Osteogenic Differentiation ◽  
Human Platelet ◽  
Human Mesenchymal Stem Cells ◽  
Platelet Lysate ◽  
Hybrid Hydrogel ◽  
Hybrid Hydrogels ◽  
Human Platelet Lysate

Bone marrow and adipose tissue human mesenchymal stem cells were seeded in highly performing 3D gelatin–chitosan hybrid hydrogels of varying chitosan content in the presence of human platelet lysate and evaluated for their proliferation and osteogenic differentiation. Both bone marrow and adipose tissue human mesenchymal stem cells in gelatin–chitosan hybrid hydrogel 1 (chitosan content 8.1%) or gelatin–chitosan hybrid hydrogel 2 (chitosan 14.9%) showed high levels of viability (80%–90%), and their proliferation and osteogenic differentiation was significantly higher with human platelet lysate compared to fetal bovine serum, particularly in gelatin–chitosan hybrid hydrogel 1. Mineralization was detected early, after 21 days of culture, when human platelet lysate was used in the presence of osteogenic stimuli. Proteomic characterization of human platelet lysate highlighted 59 proteins mainly involved in functions related to cell adhesion, cellular repairing mechanisms, and regulation of cell differentiation. In conclusion, the combination of our gelatin–chitosan hybrid hydrogels with hPL represents a promising strategy for bone regenerative medicine using human mesenchymal stem cells.

scholarly journals Human Platelet Lysate versus Fetal Calf Serum: These Supplements Do Not Select for Different Mesenchymal Stromal Cells

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Eduardo Fernandez-Rebollo ◽  
Birgit Mentrup ◽  
Regina Ebert ◽  
Julia Franzen ◽  
Giulio Abagnale ◽  
...  
Keyword(s):  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Fetal Calf Serum ◽  
Human Platelet ◽  
Calf Serum ◽  
Platelet Lysate ◽  
Human Platelet Lysate

Human platelet lysate is a feasible candidate to replace fetal calf serum as medium supplement for blood vascular and lymphatic endothelial cells

Cytotherapy ◽  
2014 ◽  
Vol 16 (9) ◽  
pp. 1238-1244 ◽  
Author(s):  
Pablo Hofbauer ◽  
Sabrina Riedl ◽  
Karin Witzeneder ◽  
Florian Hildner ◽  
Susanne Wolbank ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Fetal Calf Serum ◽  
Human Platelet ◽  
Calf Serum ◽  
Platelet Lysate ◽  
Lymphatic Endothelial Cells ◽  
Medium Supplement ◽  
Human Platelet Lysate

scholarly journals Proliferation and Differentiation of Intestinal Caco-2 Cells Are Maintained in Culture with Human Platelet Lysate Instead of Fetal Calf Serum

Cells ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 3038
Author(s):  
Dalanda Wanes ◽  
Hassan Y. Naim ◽  
Franziska Dengler
Keyword(s):  
Cell Viability ◽  
Fetal Calf Serum ◽  
Human Platelet ◽  
Calf Serum ◽  
Platelet Lysate ◽  
Model Systems ◽  
Structural Protein ◽  
Cell Extracts ◽  
Gene And Protein Expression ◽  
Human Platelet Lysate

Cell lines are widely used as in vitro model systems and substitute for animal experiments. The frequently used Caco-2 cell line is considered to reflect characteristics of differentiated intestinal epithelium. However, the need to culture the cells with fetal calf serum (FCS) induces a high variability, risk of contamination and is ethically disputed. We tested the culture of Caco-2 cells with human platelet lysate (PL) instead of FCS. We compared cell viability and differentiation by measuring ATP levels, gene and protein expression of specific markers in total cell extracts, brush border membrane vesicles (BBM) and lipid rafts (LR). Cell viability was slightly enhanced in cells grown with PL compared to FCS. The cells differentiated to an intestinal phenotype like the cells cultured in FCS, as indicated by the similar gene expression levels of hexose and protein transport proteins and the structural protein VILLIN. BBM showed a comparable distribution of the intestinal hydrolases, indicating a maintained cell membrane polarity. The distribution of the marker protein FLOTILLIN-2 in LR was also similar. We conclude that PL is an exquisite and suitable replacement for FCS in the culture of Caco-2 cells that can eliminate many disadvantages incurred due to the use of FCS.

Abstract 23: Intracerebral Transplantation of Autologous Bone Marrow Stem Cell (BMSC) for Subacute Ischemic Stroke, Phase 1 Clinical Trial (RAINBOW Trial)

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Masahito Kawabori ◽  
Hideo Shichinohe ◽  
Satoshi Kuroda ◽  
Kiyohiro Houkin
Keyword(s):  
Bone Marrow ◽  
Ischemic Stroke ◽  
Cell Tracking ◽  
Human Platelet ◽  
Phase 1 ◽  
Photon Emission ◽  
Platelet Lysate ◽  
Emission Computed Tomography ◽  
Intracerebral Transplantation ◽  
Human Platelet Lysate

Background: Recent breakthrough in cell therapy is expected to reverse the neurological sequelae of stroke. We investigated the safety and feasibility of intracerebral transplantation of autologous BMSC in the subacute phase of stroke (RAINBOW trial). Several new aspects including cell labeling and tracking, socioecomonic analysis using QALY, and the use of human platelet lysate instead of fetal bovine serum were adopted. (UNIN ID: UMIN000026130) Methods/Design: This is a phase 1, open-label, uncontrolled, dose-response study enrolling adults with severe motor deficits (mRS>3) 14 days after stroke. Approximately 50 mL of the bone marrow is extracted from the iliac bone of each patient 15 days or later from the onset, and BMSCs are cultured with allogeneic human platelet lysate (PL) and are labeled with superparamagnetic iron oxide for cell tracking using MRI. BMSCs are stereotactically administered around the area of infarction approximately 2 months from the ischemic stroke. Each patient will be administered a dose of 20 or 50 million cells. Neurological scoring, MRI for cell tracking, 18 F-fuorodeoxyglucose positron emission tomography, and 123 I-Iomazenil single photon emission computed tomography will be performed throughout 1 year after the administration. Results: All 7 patients have been successfully finished transplantation, and there was no severe adverse event in any of the patient regarding the surgical procedure nor cell quality. Favorable motor recoveries (change in mRS > 1) are seen in 5 of 7 patients, and cell engraftment and migration to ischemic site was also observed. Discussion: This is a first-in-human trial to use labelled BMSC to the patients with subacute ischemic stroke. Intracerebral transplantation of autologous BMSC is safe and well tolerated. Cell migration to the ischemic boundary can clarify the therapeutic mechanisms.

Sign in / Sign up

Export Citation Format

Share Document